Arovella Therapeutics Ltd (ASX:ALA) has presented data describing the key benefits of its proprietary iNKT cell platform and lead product ALA-101 at the prestigious 5th Annual Allogeneic Cell Therapies Summit in Boston.
This summit is the leading industry-focused meeting dedicated to accelerating the best 'off-the-shelf' cell therapies to deliver affordable and accessible treatments for cancer patients in critical need.
The biotechnology company’s chief executive officer and managing director Dr Michael Baker showcased Arovella’s iNKT cell platform as a truly 'off-the-shelf' therapy with the potential to improve efficacy across various oncology indications.
Global recognition
“It is an honour to be invited to present at such an important conference in the field of allogeneic, or off-the-shelf cell therapies and for Arovella to be recognised as a world leader in off-the-shelf treatments,” Baker said.
During the meeting, Baker touched on:
- The 'off-the-shelf' capabilities of Arovella’s CAR-iNKT platform;
- Potential benefits of CAR-iNKT cells over CAR-T in treating cancers;
- Key advantages of Arovella’s proprietary manufacturing process;
- The enhanced tumour killing of CAR19-iNKT cells (ALA-101) relative to CAR-T cells;
- The significant survival benefit conferred by ALA-101 in multiple animal models;
- The capacity of ALA-101 cells to expand and multiply in response to tumour cells;
- The potential of ALA-101 in combination with Imugene’s onCARlytics platform to treat solid tumours; and
- The possibility of Arovella’s proprietary iNKT cell platform with novel CARs to target solid tumours.
To view the full presentation, click here.
About the company
Arovella Therapeutics is a biotechnology company focused on developing therapies to treat human diseases. The company is developing its invariant natural killer T (iNKT) cell therapy platform with research partner Imperial College London to treat blood cancers and solid tumours.
Arovella is also expanding its DKK1-peptide targeting technology licensed from MD Anderson and used in conjunction with its iNKT cell therapy platform and commercialising ZolpiMist™, a first-in-class oral spray of zolpidem tartrate to treat short-term insomnia.
ZolpiMist is approved by the FDA and the TGA and marketed in the US. Arovella has rights to the product outside of the US and Canada.